Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thalys Medical Technology Group ROE % Adjusted to Book Value Chart
SHSE:603716 vs TMO, DHR, IDXX: ROE % Adjusted to Book Value Comparison
For the Diagnostics & Research subindustry, Thalys Medical Technology Group's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Thalys Medical Technology Group ROE % Adjusted to Book Value vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Thalys Medical Technology Group's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where Thalys Medical Technology Group's ROE % Adjusted to Book Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROE % Adjusted to Book Value of -1.41% mean?
Thalys Medical Technology Group (SHSE:603716) has a ROE % Adjusted to Book Value of -1.41% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Thalys Medical Technology Group and its competitors.
Is Thalys Medical Technology Group's ROE % Adjusted to Book Value too high?
Thalys Medical Technology Group's current ROE % Adjusted to Book Value is -1.41%. Overall, Thalys Medical Technology Group has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Thalys Medical Technology Group's ROE % Adjusted to Book Value compare to TMO and DHR?
Thalys Medical Technology Group's ROE % Adjusted to Book Value of -1.41% can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Medical Diagnostics & Research company?
A good ROE % Adjusted to Book Value depends on the Medical Diagnostics & Research industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Thalys Medical Technology Group and its competitors. Thalys Medical Technology Group's current ROE % Adjusted to Book Value is -1.41%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Thalys Medical Technology Group stock overvalued right now?
Based on GuruFocus' analysis, Thalys Medical Technology Group (SHSE:603716) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥4.70, compared to a current price of ¥15.89 — trading 238.1% above its estimated fair value. The current ROE % Adjusted to Book Value is -1.41%. Thalys Medical Technology Group's overall GF Score™ is 39/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Thalys Medical Technology Group (SHSE:603716), the current ROE % Adjusted to Book Value is -1.41% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Thalys Medical Technology Group (SHSE:603716) Overvalued in 2026?
Based on GuruFocus' analysis, Thalys Medical Technology Group stock appears to be overvalued.
The current stock price of ¥15.89 is trading 238.1% above its estimated GF Value™ of ¥4.70.
GuruFocus considers Thalys Medical Technology Group to be Significantly Overvalued.
Key valuation signals for SHSE:603716:
ROE % Adjusted to Book Value: -1.41%
GF Value™: ¥4.70 vs. price of ¥15.89 (238.1% above fair value)
No single metric tells the full story. See the SHSE:603716 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Thalys Medical Technology Group Corp is engaged in intensive sales business, pure sales, and research and development, production and sales of independent in vitro diagnostic products.
39GF Score
Get the complete analysis for SHSE:603716
ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603716 has been successfully added to your 
